Beam Therapeutics Inc

Beam Therapeutics CEO’s Rule 10b5‑1 trades reveal a disciplined, long‑term confidence strategy, boosting ownership while generating modest liquidity.

Beam Therapeutics insider buying signals: SVP Finance Bethany Cavanagh’s 40k stock‑option purchase amid 52‑week lows hints at long‑term confidence in DNA base‑editing breakthroughs.

Beam Therapeutics insider selling: SVP of Finance sells 6,198 shares at $35 on Jan 22, 2026 – a routine 10b5‑1 plan move amid rising investor buzz and positive monthly gains.